{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T23:21:25Z","timestamp":1793661685785,"version":"4.5.1"},"reference-count":29,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,5,8]],"date-time":"2023-05-08T00:00:00Z","timestamp":1683504000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100006436","name":"Bristol-Myers Squibb Co Summit","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006436","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100002491","name":"Bristol-Myers Squibb","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002491","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cghjournal.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Gastroenterology and Hepatology"],"published-print":{"date-parts":[[2024,1]]},"DOI":"10.1016\/j.cgh.2023.04.011","type":"journal-article","created":{"date-parts":[[2023,4,23]],"date-time":"2023-04-23T19:28:23Z","timestamp":1682278103000},"page":"102-112.e9","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":106,"title":["Pegbelfermin in Patients With Nonalcoholic Steatohepatitis and Stage 3 Fibrosis (FALCON 1): A Randomized Phase 2b Study"],"prefix":"10.1016","volume":"22","author":[{"given":"Rohit","family":"Loomba","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arun J.","family":"Sanyal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atsushi","family":"Nakajima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brent A.","family":"Neuschwander-Tetri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zachary D.","family":"Goodman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen A.","family":"Harrison","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric J.","family":"Lawitz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nadege","family":"Gunn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kento","family":"Imajo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natarajan","family":"Ravendhran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takemi","family":"Akahane","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bradly","family":"Boone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masayuki","family":"Yamaguchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arkendu","family":"Chatterjee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giridhar S.","family":"Tirucherai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diane E.","family":"Shevell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuyan","family":"Du","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4556-8850","authenticated-orcid":false,"given":"Edgar D.","family":"Charles","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manal F.","family":"Abdelmalek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.cgh.2023.04.011_bib1","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1002\/hep.29367","article-title":"The diagnosis and management of nonalcoholic fatty liver disease: practice guidance from the American Association for the Study of Liver Diseases","volume":"67","author":"Chalasani","year":"2018","journal-title":"Hepatology"},{"key":"10.1016\/j.cgh.2023.04.011_bib2","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1038\/ajg.2017.5","article-title":"Prevalence of nonalcoholic steatohepatitis-associated cirrhosis in the United States: an analysis of National Health and Nutrition Examination Survey data","volume":"112","author":"Kabbany","year":"2017","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.cgh.2023.04.011_bib3","doi-asserted-by":"crossref","first-page":"2838","DOI":"10.1016\/j.cgh.2021.12.015","article-title":"Prevalence of high and moderate risk nonalcoholic fatty liver disease among adults in the United States, 1999-2016","volume":"20","author":"Golabi","year":"2022","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.cgh.2023.04.011_bib4","doi-asserted-by":"crossref","first-page":"1559","DOI":"10.1056\/NEJMoa2029349","article-title":"Prospective study of outcomes in adults with nonalcoholic fatty liver disease","volume":"385","author":"Sanyal","year":"2021","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.cgh.2023.04.011_bib5","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1016\/j.cgh.2022.04.014","article-title":"Mortality outcomes by fibrosis stage in nonalcoholic fatty liver disease: a systematic review and meta-analysis","volume":"21","author":"Ng","year":"2023","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.cgh.2023.04.011_bib6","doi-asserted-by":"crossref","first-page":"1392","DOI":"10.1002\/hep.27678","article-title":"Challenges and opportunities in drug and biomarker development for nonalcoholic steatohepatitis: findings and recommendations from an American Association for the Study of Liver Diseases-U.S. Food and Drug Administration Joint Workshop","volume":"61","author":"Sanyal","year":"2015","journal-title":"Hepatology"},{"key":"10.1016\/j.cgh.2023.04.011_bib7","doi-asserted-by":"crossref","DOI":"10.1016\/j.molmet.2020.101152","article-title":"FGF19 and FGF21: in NASH we trust","volume":"46","author":"Talukdar","year":"2021","journal-title":"Mol Metab"},{"key":"10.1016\/j.cgh.2023.04.011_bib8","doi-asserted-by":"crossref","first-page":"10853","DOI":"10.1073\/pnas.0904187106","article-title":"FGF21 induces PGC-1alpha and regulates carbohydrate and fatty acid metabolism during the adaptive starvation response","volume":"106","author":"Potthoff","year":"2009","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.cgh.2023.04.011_bib9","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1016\/j.cmet.2007.05.002","article-title":"Hepatic fibroblast growth factor 21 is regulated by PPARalpha and is a key mediator of hepatic lipid metabolism in ketotic states","volume":"5","author":"Badman","year":"2007","journal-title":"Cell Metab"},{"key":"10.1016\/j.cgh.2023.04.011_bib10","doi-asserted-by":"crossref","first-page":"4057","DOI":"10.2337\/db14-0595","article-title":"Circulating FGF21 is liver derived and enhances glucose uptake during refeeding and overfeeding","volume":"63","author":"Markan","year":"2014","journal-title":"Diabetes"},{"key":"10.1016\/j.cgh.2023.04.011_bib11","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1016\/j.cmet.2013.03.019","article-title":"An FGF21-adiponectin-ceramide axis controls energy expenditure and insulin action in mice","volume":"17","author":"Holland","year":"2013","journal-title":"Cell Metab"},{"key":"10.1016\/j.cgh.2023.04.011_bib12","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1111\/j.1463-1326.2009.01176.x","article-title":"The role of adiponectin in the pathogenesis and treatment of non-alcoholic fatty liver disease","volume":"12","author":"Polyzos","year":"2010","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.cgh.2023.04.011_bib13","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1053\/j.gastro.2014.07.044","article-title":"Fibroblast growth factor 21 limits lipotoxicity by promoting hepatic fatty acid activation in mice on methionine and choline-deficient diets","volume":"147","author":"Fisher","year":"2014","journal-title":"Gastroenterology"},{"key":"10.1016\/j.cgh.2023.04.011_bib14","doi-asserted-by":"crossref","first-page":"S390","DOI":"10.1016\/S0168-8278(18)31013-4","article-title":"Effects of a PEGylated fibroblast growth factor 21 variant on steatosis, inflammation, and fibrosis in a mouse model of nonalcoholic steatohepatitis [abstract]","volume":"68","author":"Zinker","year":"2018","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.cgh.2023.04.011_bib15","doi-asserted-by":"crossref","first-page":"S396","DOI":"10.1016\/S0168-8278(18)31028-6","article-title":"BMS-986036, a PEGylated fibroblast growth factor 21 analogue, reduces fibrosis and PRO-C3 in a mouse model of nonalcoholic steatohepatitis [abstract]","volume":"68","author":"Luo","year":"2018","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.cgh.2023.04.011_bib16","doi-asserted-by":"crossref","first-page":"S404","DOI":"10.1016\/S0168-8278(18)31044-4","article-title":"A\u00a0PEGylated fibroblast growth factor 21 variant improves hepatic steatosis in a mouse model of nonalcoholic steatohepatitis, as determined by magnetic resonance imaging-derived hepatic fat-fraction [abstract]","volume":"68","author":"Tang","year":"2018","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.cgh.2023.04.011_bib17","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1002\/oby.22344","article-title":"Pegbelfermin (BMS-986036), PEGylated FGF21, in patients with obesity and type 2 diabetes: results from a randomized phase 2 study","volume":"27","author":"Charles","year":"2019","journal-title":"Obesity"},{"key":"10.1016\/j.cgh.2023.04.011_bib18","doi-asserted-by":"crossref","first-page":"2705","DOI":"10.1016\/S0140-6736(18)31785-9","article-title":"Pegbelfermin (BMS-986036), a PEGylated fibroblast growth factor 21 analogue, in patients with non-alcoholic steatohepatitis: a randomised, double-blind, placebo-controlled, phase 2a trial","volume":"392","author":"Sanyal","year":"2018","journal-title":"Lancet"},{"key":"10.1016\/j.cgh.2023.04.011_bib19","doi-asserted-by":"crossref","DOI":"10.1016\/j.cct.2021.106335","article-title":"The FALCON program: two phase 2b randomized, double-blind, placebo-controlled studies to assess the efficacy and safety of pegbelfermin in the treatment of patients with nonalcoholic steatohepatitis and bridging fibrosis or compensated cirrhosis","volume":"104","author":"Abdelmalek","year":"2021","journal-title":"Contemp Clin Trials"},{"key":"10.1016\/j.cgh.2023.04.011_bib20","article-title":"Determining a healthy reference range and factors potentially influencing PRO-C3 \u2013 a biomarker of liver fibrosis","volume":"3","author":"Erhardtsen","year":"2021","journal-title":"JHEP Rep"},{"key":"10.1016\/j.cgh.2023.04.011_bib21","doi-asserted-by":"crossref","first-page":"1140","DOI":"10.1053\/j.gastro.2018.07.006","article-title":"Simtuzumab is ineffective for patients with bridging fibrosis or compensated cirrhosis caused by nonalcoholic steatohepatitis","volume":"155","author":"Harrison","year":"2018","journal-title":"Gastroenterol"},{"key":"10.1016\/j.cgh.2023.04.011_bib22","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.jhep.2020.02.027","article-title":"Selonsertib for patients with bridging fibrosis or compensated cirrhosis due to NASH: results from randomized phase III STELLAR trials","volume":"73","author":"Harrison","year":"2020","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.cgh.2023.04.011_bib23","doi-asserted-by":"crossref","first-page":"1913","DOI":"10.1002\/hep.30664","article-title":"The natural history of advanced fibrosis due to nonalcoholic steatohepatitis: data from the simtuzumab trials","volume":"70","author":"Sanyal","year":"2019","journal-title":"Hepatology"},{"key":"10.1016\/j.cgh.2023.04.011_bib24","doi-asserted-by":"crossref","first-page":"e798","DOI":"10.1016\/S0618-8278(19)31589-0","article-title":"Pharmacokinetics and safety of pegbelfermin (BMS-986036) administered in the abdomen and upper arm to normal, overweight, and obese healthy participants [abstract]","volume":"70","author":"Tirucherai","year":"2019","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.cgh.2023.04.011_bib25","doi-asserted-by":"crossref","first-page":"1262","DOI":"10.1038\/s41591-021-01425-3","article-title":"Efruxifermin in non-alcoholic steatohepatitis: a randomized, double-blind, placebo-controlled, phase 2a trial","volume":"27","author":"Harrison","year":"2021","journal-title":"Nat Med"},{"key":"10.1016\/j.cgh.2023.04.011_bib26","doi-asserted-by":"crossref","DOI":"10.1016\/j.taap.2021.115673","article-title":"Pegbelfermin, a PEGylated FGF21 analogue, has pharmacology without bone toxicity after 1-year dosing in skeletally mature monkeys","volume":"428","author":"Thompson","year":"2021","journal-title":"Toxicol Appl Pharmacol"},{"key":"10.1016\/j.cgh.2023.04.011_bib27","article-title":"Effect of pegbelfermin on NASH and fibrosis-related biomarkers and correlation with histological response in the FALCON 1 trial","volume":"5","author":"Brown","year":"2023","journal-title":"JHEP Rep"},{"key":"10.1016\/j.cgh.2023.04.011_bib28","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.1002\/hep.20701","article-title":"Design and validation of a histological scoring system for nonalcoholic fatty liver disease","volume":"41","author":"Kleiner","year":"2005","journal-title":"Hepatology"},{"key":"10.1016\/j.cgh.2023.04.011_bib29","doi-asserted-by":"crossref","DOI":"10.1016\/j.cct.2019.105922","article-title":"Cenicriviroc for the treatment of liver fibrosis in adults with nonalcoholic steatohepatitis: AURORA Phase 3 study design","volume":"89","author":"Anstee","year":"2020","journal-title":"Contemp Clin Trials"}],"container-title":["Clinical Gastroenterology and Hepatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1542356523003105?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1542356523003105?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T05:45:19Z","timestamp":1761543919000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1542356523003105"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1]]},"references-count":29,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2024,1]]}},"alternative-id":["S1542356523003105"],"URL":"https:\/\/doi.org\/10.1016\/j.cgh.2023.04.011","relation":{},"ISSN":["1542-3565"],"issn-type":[{"value":"1542-3565","type":"print"}],"subject":[],"published":{"date-parts":[[2024,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Pegbelfermin in Patients With Nonalcoholic Steatohepatitis and Stage 3 Fibrosis (FALCON 1): A Randomized Phase 2b Study","name":"articletitle","label":"Article Title"},{"value":"Clinical Gastroenterology and Hepatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cgh.2023.04.011","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 by the AGA Institute. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}